World Health Organization Issues Alert Over Severe Lack of Obesity Medications
Fewer than one in 10 people that would benefit from obesity jabs like Wegovy are able to get them, states the WHO as it issues its inaugural guidance on the drugs.
Given more than one billion people worldwide now obese, it is calling for increased and just availability to these injectable treatments.
Per projections, in excess of 2,000,000,000 are projected to be obese by 2030 unless action is taken.
"The latest guidelines recognises that excess weight is a chronic disease that can be addressed with comprehensive and ongoing treatment," stated its chief Tedros Adhanom Ghebreyesus.
Significant expense, insufficient output, and logistical bottlenecks are major barriers to broad availability to the jabs that can assist patients in reducing significant weight, explains the organization.
GLP-1 Therapy Scarcity
Despite the current most optimistic outlook, the production of these medications might only reach around 100 million people โ less than 10% of those who need them, as stated by the WHO.
The advice urges countries and companies to widen access, through measures like licensing agreements.
A patent on semaglutide โ the core ingredient of a leading brand โ is due to expire in a number of nations in 2026.
The Way Obesity Injections Work
These medications mimick a body's own hormone to delay gastric emptying, curb appetite and boost the sense of being full so individuals reduce food intake.
Individuals commonly start to lose weight after several weeks of commencing the once-weekly jabs.
Studies suggests patients may put most of the weight back on a year later of discontinuing the treatment, when their usual hunger return.
Being above a healthy weight increases your likelihood for experiencing health problems, including diabetes, cardiovascular issues, brain attack, and specific malignancies.
Obesity concerns people in countries worldwide and was associated with over three and a half million fatalities worldwide in 2024, according to the WHO.
